BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8198928)

  • 1. Dose of midazolam should be reduced during diltiazem and verapamil treatments.
    Backman JT; Olkkola KT; Aranko K; Himberg JJ; Neuvonen PJ
    Br J Clin Pharmacol; 1994 Mar; 37(3):221-5. PubMed ID: 8198928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azithromycin does not increase plasma concentrations of oral midazolam.
    Backman JT; Olkkola KT; Neuvonen PJ
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):356-9. PubMed ID: 7582388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.
    Palkama VJ; Ahonen J; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 1999 Jul; 66(1):33-9. PubMed ID: 10430107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting.
    Ahonen J; Olkkola KT; Salmenperä M; Hynynen M; Neuvonen PJ
    Anesthesiology; 1996 Dec; 85(6):1246-52. PubMed ID: 8968170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone.
    Lamberg TS; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Jun; 63(6):640-5. PubMed ID: 9663178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diltiazem enhances the effects of triazolam by inhibiting its metabolism.
    Varhe A; Olkkola KT; Neuvonen PJ
    Clin Pharmacol Ther; 1996 Apr; 59(4):369-75. PubMed ID: 8612379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifampin drastically reduces plasma concentrations and effects of oral midazolam.
    Backman JT; Olkkola KT; Neuvonen PJ
    Clin Pharmacol Ther; 1996 Jan; 59(1):7-13. PubMed ID: 8549036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced effect of triazolam with diltiazem.
    Kosuge K; Nishimoto M; Kimura M; Umemura K; Nakashima M; Ohashi K
    Br J Clin Pharmacol; 1997 Apr; 43(4):367-72. PubMed ID: 9146848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers.
    Ahonen J; Olkkola KT; Neuvonen PJ
    Br J Clin Pharmacol; 1995 Sep; 40(3):270-2. PubMed ID: 8527290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potentially hazardous interaction between erythromycin and midazolam.
    Olkkola KT; Aranko K; Luurila H; Hiller A; Saarnivaara L; Himberg JJ; Neuvonen PJ
    Clin Pharmacol Ther; 1993 Mar; 53(3):298-305. PubMed ID: 8453848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic interaction between roxithromycin and midazolam.
    Backman JT; Aranko K; Himberg JJ; Olkkola KT
    Eur J Clin Pharmacol; 1994; 46(6):551-5. PubMed ID: 7995324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.
    Olkkola KT; Ahonen J; Neuvonen PJ
    Anesth Analg; 1996 Mar; 82(3):511-6. PubMed ID: 8623953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.
    Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 2006 Apr; 79(4):362-70. PubMed ID: 16580904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of metronidazole on midazolam metabolism in vitro and in vivo.
    Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Eur J Clin Pharmacol; 2000 Nov; 56(8):555-9. PubMed ID: 11151744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine.
    Hermann DJ; Krol TF; Dukes GE; Hussey EK; Danis M; Han YH; Powell JR; Hak LJ
    J Clin Pharmacol; 1992 Feb; 32(2):176-83. PubMed ID: 1613128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans.
    Abernethy DR; Egan JM; Dickinson TH; Carrum G
    J Pharmacol Exp Ther; 1988 Mar; 244(3):994-9. PubMed ID: 3252045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?
    Friedman EJ; Fraser IP; Wang YH; Bergman AJ; Li CC; Larson PJ; Chodakewitz J; Wagner JA; Stoch SA
    J Clin Pharmacol; 2011 Nov; 51(11):1561-70. PubMed ID: 21209240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker.
    Ohashi K; Sudo T; Sakamoto K; Tateishi T; Fujimura A; Kumagai Y; Shiga T; Ebihara A
    Int J Clin Pharmacol Ther Toxicol; 1992 Aug; 30(8):271-4. PubMed ID: 1526689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular interactions of lidocaine with verapamil or diltiazem in the dog.
    Kapur PA; Grogan DL; Fournier DJ
    Anesthesiology; 1988 Jan; 68(1):79-85. PubMed ID: 3337393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
    Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
    Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.